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Abstract 
Study Design. In vivo study of anterior discectomy and fusion using a bioresorbable 70:30 poly(l-
lactide-co-d,l-lactide) interbody implant in an ovine model. 
Objective. To evaluate the efficacy of the polylactide implant to function as an interbody fusion 
device, and to assess the tissue reaction to the material during the resorption process. 
Summary of Background Data. The use of polylactide as a cervical interbody implant has several 
potential advantages when compared with traditional materials. Having an elastic modulus very 
similar to bone minimizes the potential for stress shielding, and as the material resorbs additional 
loading is transferred to the developing fusion mass. Although preclinical and clinical studies have 
demonstrated the suitability of polylactide implants for lumbar interbody fusion, detailed 
information on cervical anterior cervical discectomy and fusion (ACDF) with polylactide devices is 
desirable. 
Methods. Single level ACDF was performed in 8 skeletally mature ewes. Bioresorbable 70:30 poly (l-
lactide-co-d,l-lactide) interbody implants packed with autograft were used with single-level metallic 
plates. Radiographs were made every 3 months up to 1 year, and yearly thereafter. The animals 
were killed at 6 months (3 animals), 12 months (3 animals), and 36 months (2 animals). In addition to 
the serial plain radiographs, the specimens were evaluated by nondestructive biomechanical testing 
and undecalcified histologic analysis. 
Results. The bioresorbable polylactide implants were effective in achieving interbody fusion. The 6-
month animals appeared fused radiographically and biomechanically, whereas histologic sections 
demonstrated partial fusion (in 3 of 3 animals). Radiographic fusion was confirmed histologically and 
biomechanically at 12 months (3 of 3 animals) and 36 months (2 of 2 animals). A mild chronic 
inflammatory response to the resorbing polylactide implant was observed at both 6 months and 12 
months. At 36 months, the operative levels were solidly fused and the implants were completely 
resorbed. No adverse tissue response was observed in any animal at any time period. 
Conclusion. Interbody fusion was achieved using bioresorbable polylactide implants, with no 
evidence of implant collapse, extrusion, or adverse tissue response to the material. The use of 
polylactide as a cervical interbody device appears both safe and effective based on these ACDF 
animal model results. 
 
Among the management options for degenerative or traumatic conditions of the cervical spine, 
anterior cervical discectomy and fusion (ACDF) continues to be the most popular. The inherent 
advantages of the anterior approach include its direct muscle sparing approach leading to an 
unencumbered visualization of the spinal cord and exiting nerve roots, the benefit of complete 
removal of the degenerative or traumatized intervertebral disc, and the presence of 2 endplates 
with substantial surface area to yield high fusion rates. Single level ACDF has consistently yielded 
high fusion rates along with a high rate of clinical success in the amelioration of symptoms referable 
to nerve root or spinal cord compression. The major debate remaining centers on the use of 
allograft versus autograft.1-3 
Autologous graft, harvested from either the iliac crest bone or fibula, has demonstrated low 
nonunion rates, but the complications associated with these procedures have all but eliminated their 
popularity. The principal complications include infection, hematoma, lateral femoral cutaneous 
nerve palsy, and chronic pain.4 Conversely, the use of allograft raises issues, such as the potential for 
disease transmission, increased cost and nonunion. 
Intervertebral cages have emerged as an alternative to bone graft with the stated advantages of 
negligible incidence of collapse (leading to kyphosis) and pseudarthrosis.5 The composition of these 
cages has been the focus of a significant body of research. Metals such as titanium and stainless 
steel are common implant materials but obscure subsequent radiologic studies, particularly at the 
developing fusion site. Other biomaterials such as hydroxylapatite and other calcium phosphate 
ceramics are subject to fracture, collapse, and extrusion.6 
To address these issues, interbody implants made from bioresorbable materials have been studied 
as an alternative to structural bone grafts or metallic implants to facilitate fusion. Generally the 
limitations of the use of bioresorbable materials are because of the relatively lower initial strength 
and the decrease in strength during the polymer degradation process (which begins immediately 
after implantation), and whether the implant will provide sufficient strength or stability for the 
intended application. Conversely, bioresorbable polymers have the advantage of radiolucency 
facilitating greater detail on radiologic imaging without the scatter effect metallic components have 
on computed tomography (CT) and magnetic resonance imaging. Stress shielding associated with 
metallic implants is lessened because the material's elastic modulus is close to that of bone, and 
because there is a gradual increasing transfer of the load across the fusion site as the implant is 
resorbed. For example, van Dijk et al demonstrated a significantly higher rate of fusion using stand 
alone cages made of poly(l-lactide) when compared with titanium.7,8 
In addition for a bioresorbable implant, there must be minimal reaction to the degradation products 
to minimize the possibility of an adverse tissue response (for example a foreign body or osetoclastic 
resorption response). When compared with other bioresorbable materials, such as those consisting 
of only l-lactide or copolymers containing glycolide, poly(l-lactide-co-d,l-lactide) has been reported 
to elicit much less of a tissue reaction.9-13 Numerous review articles are available in the literature 
describing the chemical, physical, and mechanical properties of these materials, as well as the 
mechanisms of degradation and the body's reaction to the materials and the breakdown 
products.14-19 Recently, reviews have summarized specifically the preclinical and clinical literature 
demonstrating the potential of bioresorbable materials as interbody implants.20-24 
In the present study, we evaluated the safety and efficacy of cervical interbody implant made from 
high molecular weight, amorphous 70:30 poly(l-lactide-co-d,l-lactide) in an ovine ACDF model. 
 
Materials and Methods 
Implants 
The bioresorbable interbody implants were fabricated by MacroPore Biosurgery (San Diego, CA) 
from commercially available 70:30 poly(l-lactide-co-d,l-lactide), or PLDLLa, raw material (Boehringer-
Ingelheim, Ingelheim, Germany). The raw material consists of a random arrangement of 70% l-
lactide, and 30% d,l-lactide; within the 30% d,l-lactide, there is 50% l-lactide and 50% d-lactide, also 
in a random arrangement. Thus the material is a random arrangement of 85% l-lactide and 15% d-
lactide. The specifications for the raw material included an inherent viscosity of 5.5 to 6.5 dL/g, and 
residual monomer less than 0.5%. The raw material molecular weight (Mw, weight average) was 
approximately 950,000 to 1,000,000 g/mol. As manufactured, this 70:30 PLDLLa material has been 
shown to retain up to 100% of its initial compressive strength after 26 weeks,25 or longer depending 
on the implant design, indicating its potential for interbody applications. In vitro ageing of devices of 
the same design as in the present study (but with 10 mm height and a 2.5 mm wall thickness) 
withstood an initial maximum compressive load of 5633 N and maintained 99% of this compressive 
strength to 52 weeks (unpublished data, MacroPore Biosurgery). Polymer analysis also 
demonstrated the material was amorphous (no crystallinity) in various fabricated forms for up to 52 
weeks or longer.26,27 
All implants were fabricated, packaged, and sterilized using qualified processes identical to those 
used for manufacturing of commercial implants from the 70:30 PLDLLa raw material. The implants 
were fabricated by injection molding, followed by machining of features into the final implant 
shape. The implants measured 11 x 11 x 7 mm (width x length x height), with a central open region 
(hole) and a 2 mm wall thickness. The device had flat endplates with parallel notches to limit 
migration, slightly converging lateral sides, and a curved anterior (ventral) aspect. Tantalum 
markers (0.5 mm O) were inserted into each device, 1 anteriorly and 2 posteriorly, to allow 
radiographic monitoring of the radiolucent implant. The bioresorbable interbody implant is shown 
in Figure 1. All samples were placed in standard packaging and sterilized by electron beam (e-
beam) by a commercial medical device sterilization vendor using a standard, qualified process. 
 
In this animal study the bioresorbable interbody implants were used in conjunction with single level 
metallic plates and screws. Because of the anatomy and posture of the animals, and the impossibility 
of restricting movement of the cervical spine, the plates prevented early extrusion of the interbody 
implant. The use of plates in this model is similar to common clinical practice for patients who desire 
an earlier return to activities of daily living or the workplace, who may have comorbidities that may 
affect their ability to fuse, or who may be noncompliant regarding the use of an orthosis. 
Surgical Procedures 
Under an IACUC approved protocol, 8 skeletally mature Rambouillet x Columbian ewes were 
anesthetized using diazepam (0.1 mg/kg, IV) and ketamine (3.3 mg/kg) for induction, and isofluorane 
inhalation (1.5%-4% in 100% oxygen at 2 L/min) for maintenance. Under anesthesia in dorsal 
recumbency, the ventral (anterior) cervical spine and sternum were clipped and prepared and 
draped for sterile surgery in a routine manner using alternating scrubs of povidone iodine and 
alcohol. An 8-cm incision was made over the sternum. After partial reflection of the skin and 
subcutaneous tissues, an osteotome was used to create a small window in the ventral cortex of the 
sternum. Using a curette, approximately 2 cm3 of autogenous cancellous bone was removed. The 
sternal incision site was closed using resorbable subcutaneous suture and stainless steel skin staples. 
Ventral (anterior) exposure and discectomy was then performed. A midline ventral (anterior) incision 
was made from the thyroid cartilage to the manubrium sternum. The paired sternohyoid and 
sternomastoid muscles were separated on their midline. The esophagus and trachea and the carotid 
sheaths were digitally retracted. At the selected disc space vertebral spreaders were applied, the 
longus coli muscles were elevated, subperiosteally, followed by discectomy. In 4 animals the C3-C4 
level was used, C4-C5 was used in 3 animals, and C5-C6 was used in 1 animal. The interior of the 
bioresorbable interbody implant was packed with cancellous autograft harvested from the sternum. 
Under distraction the endplates were removed down to bleeding bone, as parallel as possible, using 
a high-speed burr and the device implanted. To prevent anterior migration of the device, single-level 
F136 titanium alloy plates and screws were used (Atlantis Plates, Medtronic Sofamor Danek, 
Memphis, TN). The plates were 24 mm in length, and the screws were 4 mm O, 12 mm in length (4 
per animal). After plating, routine closure of the longus coli muscle (size 0 absorbable suture), 
subcutaneous tissues (size 2-0 absorbable suture), and the skin (size 2-0 nonabsorbable 
monofilament suture) were performed. 
All animals received phenylbutazone (1 g, orally) 1 day before surgery, on the day of surgery, and for 
3 days after surgery. All animals also received fentanyl (150 [mu]g/h) by transdermal patches 
beginning 1 day before surgery through the second postoperative day. Prophylactic antibiotics were 
given perioperatively (cefazolin sodium, 1 g, iv). After surgery, all animals were monitored 
continually for pain for 4 to 6 hours, and then received standard postoperative treatment and care. 
Dorsoventral (anteroposterior) and lateral radiographs were taken immediately after surgery and 
every 3 months for the first 12 months, and then every 12 months until sacrifice. 
Animals were randomly selected for termination at 6, 12, or 36 months after surgery. Euthanasia 
was achieved by pentobarbital sodium overdose, the cervical spine was harvested en bloc, including 
at least an additional level above and below the surgical site, and immediately frozen and forwarded 
for biomechanical testing. 
 
Biomechanical Testing 
Before testing, the specimens were thawed and cleaned of muscle tissues without damaging the 
ligaments, discs, or joint capsules. The metallic plates and screws were not removed before testing. 
Wood screws were partially inserted into the facet articulations and endplates, and the screw heads 
embedded in polymethylmethacrylate within cylindrical fixtures for application of the test loads. 
Nonconstraining, nondestructive pure moment (torque) loading was applied to each specimen as 
previously described.28,29 Torque loading was applied through a system of cables and pulleys in 
conjunction with a standard servo-hydraulic test system (MTS Systems, Minneapolis MN). Loading 
was applied to induce flexion, extension, left and right lateral bending, and left and right axial 
rotation. Three preconditioning cycles were first applied in each loading mode by ramping to 5.0 Nm 
and holding for 60 seconds before releasing. After preconditioning, the specimens rested for 60 
seconds, followed by loading to a maximum of 5.0 Nm, applied in increments of 1.0 Nm of 45 
seconds each. Maximum loads of 5.0 Nm were used because it was expected that this magnitude 
would more effectively demonstrate differences between fused and unfused segments than smaller 
loads sometimes used for cervical flexibility testing. Loads of 5.0 Nm are similar to those used by 
other researchers studying ovine cervical biomechanics.30-32 Motion at the operated level and the 
adjacent cranial and caudal levels in response to the applied loading was measured in three-
dimensions using the Optotrak 3020 system (Northern Digital, Waterloo, Ontario, Canada). The 
Optotrak system measured the 3-dimenional displacement of infrared light emitting markers rigidly 
fixed to each vertebra. Custom software converted the marker displacement coordinates to angles 
with respect to the anatomic axes at the index and adjacent levels.33,34 After the biomechanical 
testing, the specimens were fixed in buffered formalin and forwarded for undecalcified histologic 
and microradiographic evaluation. 
 
Histologic Evaluation 
High-resolution radiographs of the harvested spines were made using a high-resolution system 
(Faxitron, Hewlett Packard, McMinnville, OR; Ektascan B/RA 4153 film, Eastman-Kodak, Rochester, 
NY). PA and lateral radiographs were made before and after removal of the metallic plates and 
graded to assess fusion; these radiographs were also used for orientation to prepare the samples for 
histologic analysis as described below. The Faxitron radiographs were graded as follows: 1 = 
nonfusion; 2 = lucency with some bony bridging; 3 = increased bone density; 4 = continuous bony 
bridging. On the lateral radiographs, the center of the disc space as well as the anterior and posterior 
margins were evaluated; on the PA radiographs, the center of the disc space as well as the medial 
and lateral margins were evaluated. An overall fusion score for the spinal level was determined: 
Grade 1 was a nonfusion with significant radiolucent lines in the through-growth region of the 
implant; Grade 2 was a probable fusion with some radiolucent lines in the through-growth region of 
the implant; and Grade 3 was a solid interbody fusion with no radiolucent lines in the through-
growth region of the implant. 
After radiography, all spinal levels containing an implant were sectioned in the sagittal plane to 
produce 2 sagittal slabs and processed by undecalcified histology. Both slabs from each animal were 
sequentially dehydrated in alcohol, cleared in a clearing agent, and embedded in graded catalyzed 
methyl methacrylate. After polymerization was complete and the samples were hardened, the 
blocks containing explants and surrounding tissues were sectioned on diamond saws (Buehler 
Isomet, Lake Bluff, IL) to an approximate thickness of 150 to 400 [mu]m. Approximately 18 sections 
(total per spinal level) were made in the sagittal plane through the explant blocks. If necessary, 
grinding was performed to obtain the desired thickness. Differential staining using a proprietary 
multiple stain was used to permit differentiation of bone, cartilage, fibrocartilage, and fibrovascular 
tissues. Staining of cellular and nuclear detail by the trichrome stain (similar to H&E) permitted 
cytologic differentiation. 
Approximately 8 undecalcified sections from each spinal level were selected for microradiography. 
These sections were radiographed using a Faxitron radiography unit (Hewlett Packard, McMinnville, 
OR) and spectroscopic film (EM-1 film, Kodak, Rochester, NY). Sections were exposed to the 
radiograph source at 20 kV and 3 mA for approximately 45 seconds for each 100 [mu]m of section 
thickness. 
Individual undecalcified sections were evaluated for fusion in the anterior margin, in the middle 
(through-growth) region of the polylactide implant, and in the posterior margin. These anatomic 
locations for each section were considered to be fused only if continuous bony bridging was found 
from superior to inferior. Based on all sections evaluated from each spine, the spinal level was 
considered to be fused if greater than 50% of the sections showed continuous bony bridging in any 
of the 3 anatomic regions; a partial fusion existed if less than 50% of the sections showed continuous 
bony bridging in any of the 3 anatomic regions, and a nonfusion existed if none of the sections 
showed continuous bony bridging. 
To characterize the host response to the polymer implant material, and polymer degradation 
products (if present), sections were scored using ASTM F981.35 This standard was used to evaluate 
necrosis, degeneration, inflammation, fibrosis, foreign body debris, fatty infiltration, and the 
presence of giant cells/osteoclasts. While ASTM F981 does not include osteoclasts, this modification 
was used because the differentiation of giant cells from osteoclasts is not always possible in osseous 
tissues. 
Results 
There were no surgical or postoperative complications observed in any animal. Animals were killed 
at 6 and 12 months (3 animals each), and at 36 months (2 animals). 
A total of 28 sets of plain radiographs were evaluated from 3, 6, 9, 12, 24, and 36 month follow-up 
time points. In 2 animals (killed at 36 months), the 6-month follow-up radiographs were not 
available. Screw back-out occurred in 2 animals at 6 months after surgery (1 screw in each) and each 
progressed without complications thereafter (each was killed at 36 months). Radiographic evidence 
of a developing fusion was present at 3 months and confirmed at all time periods thereafter. There 
was no evidence of any significant loss of disc space (height) as the fusion developed, nor was there 
evidence of any adverse tissue reaction to the resorbing polymer material or any evidence of 
osteolysis. In no radiograph from any animal was there any evidence of movement of the implant, 
nor was there migration of any of the tantalum markers. 
 
Biomechanical Testing 
The results of the biomechanical testing are summarized for all animals in Table 1. As expected, 
there was a marked decrease in the range of motion in all loading modes at the fusion level as 
compared to the adjacent levels. The biomechanical testing indicated fusion at the 6-month time 
period, with less than 0.5[degrees] ROM at the fusion level in each loading mode. The largest ROM 
observed was in lateral bending, followed by extension, both at the adjacent caudal levels. The 
motion observed in all loading modes showed no consistent change over time from 6 to 36 
months. At the fusion level, the average ROM for all modes at all time periods was 0.23[degrees] 
(range, 0.06-0.40[degrees]). For all adjacent (unfused) levels, the average ROM for all modes at all 
time periods was 11.19[degrees] (range, 3.10-21.40[degrees]). The individual ROM results for each 
animal are shown in Figure 2. 
 
 
Radiographic Evaluation of Fusion 
Radiographic evaluation of fusion, based on the postsacrifice Faxitron radiographs, was performed 
by 2 independent evaluators blinded to survival time. For the 6 month animals, one was rated as a 
solid fusion by both evaluators, whereas the remaining 2 animals each were rated as a probable 
fusion by one evaluator and as a solid fusion by the other evaluator. All three 12-months animals 
were rated as solid fusions by both evaluators, as were the two 36-month animals. 
 
Histologic Evaluation 
Using the criteria described for evaluating the sections, there were no histologic nonfusions at any 
time period. At 6 months, all 3 of the treated levels generated partial histologic fusions, often 
limited to the anterior margins on the medial or lateral side of the levels. The 6 month, stained 
undecalcified sections and corresponding microradiographs through the center of the disc space 
 
(through center of implant) did not show continuous bony bridging from superior to inferior 
(Figure 3). The polylactide devices were intact, with evidence of fissures in the sections, and 
surrounded by quiescent fibrous tissue. All animals at 6 months were graded as having a mild 
chronic inflammatory response (score of 1.0, per ASTM F981). 
At 12 months, all treated levels (3 animals) showed a histologic fusion with continuous bony 
bridging within the polylactide device (Figure 4) In contrast to the 6-month time period, the 
polylactide implants exhibited visible resorption of features such as the peaks of the serrations 
(teeth) and corners of the device. At 1 year, some polylactide device fragments were present in 
peri-implant tissues. Quiescent fibrous tissues of varying thickness and resembling a capsule were 
present at the polylactide device interface. Interdigitations along the endplate surfaces of the 
polylactide implant were filled with bone but separated from the polylactide implant by a thin 
layer of fibrous tissue. As observed at 6 months, the tissue response of all animals was graded as 
mild chronic inflammation (score of 1.0, per ASTM F981). 
 
 
Discussion 
The comparison of results from preclinical studies is often problematic because of differences in the 
study design, implant materials, methodologies and endpoints used. With respect to bioresorbable 
materials, sufficient details are needed to completely describe the material used, including the raw 
material and the processing used to manufacture the implant studied, to insure that valid 
comparisons can be made as described below. The description of materials in general terms (e.g., 
polylactide) rather than specifically (e.g., 70:30 poly(l-lactide-co-d,l-lactide)) may at best lead to 
confusion, and at worst the idea that all bioresorbable materials are alike. 
The results of the present study, in terms of the development of fusion, were consistent with 
previous preclinical and short-term clinical studies of the same material (identically manufactured 
70:30 PLDLLa).36-39 Toth et al reported on a threaded lumbar interbody device with autograft or 
rhBMP2 in an ovine model.36 The mean radiographic scores indicated probable fusion for all animals 
at 6 and 12 months, and solid fusion at 18 months. Histologic sections showed half of the 6 months 
animals to be fused (1 of 2 animals in each group), and at 12 months 3 of 4 autograft animals and 1 
of 2 rhBMP2 animals were solid fusions. All animals at 18 and 24 months demonstrated solid 
histologic fusion, although analysis was not complete on all 24 months animals. The tissue response 
was graded as a mild to moderate inflammatory response at all time periods, with no osteolysis or 
adverse response to the degradation products of the polymer. At 24 months significant, though 
incomplete, resorption of the interbody device had occurred. The larger implant design and greater 
volume of PLDLLa used in the study by Toth et al may explain the slight difference in tissue response 
and the remaining polymer at 24 months; the influence cage design has been summarized by 
Wuisman and Smit.23 
The results of the present study are in sharp contrast to the findings reported by Kandziora et 
al.40 They reported on ACDF with plating in a sheep model using tricortical iliac crest autograft, 
70:30 poly(l-lactide-co-d,l-lactide) cages, and a polymer-calcium phosphate composite cage (8 
animals in each group). All animals were killed at 12 weeks after surgery, and the 70:30 poly(l-
lactide-co-d,l-lactide) cages were reported to be equivalent to the iliac crest autograft. However, 
they reported all of the 70:30 poly(l-lactide-co-d,l-lactide) cages to have mild (<1 mm) to severe (>3 
mm) osteolysis around the implant. In the present study, there was no suggestion of osteolysis on 
any postoperative radiograph, nor in any histologic section in any animal at 6, 12, or 36 months; the 
tissue reaction to the 70:30 PLDLLa implant and the degradation products elicited at worst a mild 
inflammatory response which was completely absent at 36 months. Wuisman et al41 have 
commented on several aspects of the work by Kandziora et al, particularly the inadequate details of 
the material used and whether the findings Kandziora reported are comparable to other preclinical 
and clinical studies of 70:30 PLDLLa. 
Clinical reports of 70:30 PLDLLa used as interbody implants in cervical ACDF are limited to 
retrospective series with relatively short-term follow-up,37-39 with no randomized, prospective 
series published to date. These limited results, however, have demonstrated good to excellent 
clinical results with a commercial implant very similar to those used in the present animal study 
(commercial device has various heights, a 2.5-mm wall thickness, and no tantalum markers; 
Cornerstone HSR implant, manufactured by MacroPore Biosurgery for Medtronic Sofamor Danek, 
Memphis, TN). Vaccaro et al37 reported on 8 patients who had single or multilevel ACDF with plating 
having good (3) to excellent (5) results by Odom's criteria, although the follow-up period was only 6 
to 7 months. At that follow-up time point, 17 of 18 levels were graded as radiographically fused. A 
group of 20 patients who received the same implant augmented with rhBMP2 were studied by 
Lanman and Hopkins.38 This cohort included ACDF with plating at a single level in 14 patients, 2 
levels in 4 patients, and 3 levels in 2 patients (total of 28 levels). Fusion was assessed by CT scan and 
defined as bone bridging in the interbody space through the bioresorbable implant. All levels were 
fused at both 3 months (28 of 28 levels in 20 patients), and at 6 months (24 of 24 levels in 17 
patients). This series was later reported at a minimum follow-up period of 12 months (range, 12-18 
months) with the cohort including 27 patients. All patients were fused at 3 months, and at a 
minimum of 12 months (by CT scan) in 42 of 42 operated levels, with no implant related 
complications.39 
In evaluating the biomechanical stability of the explanted spine segments, the metallic plates were 
left in place. Dissecting and removing the plates would have been infeasible because of the large 
overgrowth of the fusion mass and would likely have damaged the fusion mass, confounding the 
results. Therefore, the stability observed may have exceeded the stability of the fusion mass if it had 
been evaluated independently. However, it was shown previously that the ROM across incompletely 
fused plated ovine cervical motion segments with interbody spacers far exceeds the values observed 
in the present study, with mean ROM as high as 3.4[degrees] under 6 Nm load.40 Therefore the 
small ROM observed in the present study most likely represent fusion. 
The limitations of the present study include the numbers of animals used and the time points chosen 
for evaluation of the histologic endpoints. Ideally additional animals and time points would have 
been desirable, with perhaps a control group of metallic or nonresorbable interbody implants, or a 
control group with structural autograft. Additional time points between 6 and 12 months would 
have clarified the duration of the mild inflammatory response observed. To determine more 
precisely the time required for complete resorption to occur, time points between 12 and 36 months 
would have been desirable. Finally the use of metallic plates, while not a limitation per se, is 
generally required by animal care and use committees, because of the high rate of early 
complications and euthanasia in nonplated ACDF, and could introduce a confounding variable. 
In summary, the use of 70:30 PLDLLa as an interbody spacer resulted in partial histologic fusion at 6 
months and solid bony fusion at 12 and 36 months. The nondestructive biomechanical testing ROM 
data suggested all animals were fused with no ROM greater than 0.5[degrees] at the operative level. 
Because of the time points studied, it is not possible to know exactly when bony fusion occurred. 
Plain radiographs were predictive of bony fusion at 6 months, and correlated with histologic results 
for fusion thereafter. This suggests that other imaging methods may be useful in the early 
postoperative period, even with a radiolucent implant, in patients with concern regarding the status 
of their fusion. Although not a specific goal of this study, the finding of no migration of any of the 
tantalum markers suggests that the radiopaque markers were stable within the device even during 
resorption. This may suggest that the risk is low of late complications due to marker migration to an 
undesirable location, or of a "false positive" implant complication. Resorption of the 70:30 PLDLLa 
implant was associated with a mild chronic inflammatory response until 12 months, or longer, with 
complete resorption and no associated tissue response occurring between 12 and 36 months. In no 
animal at any time period was there any evidence of an adverse tissue reaction or osteolysis. 
 
 
Key Points 
* Histology demonstrated partial fusion at 6 months and complete fusion at 12 and 36 months, 
although all animals had radiographic evidence of fusion after 6 months. 
* Nondestructive biomechanical testing results were consistent with the partial or complete 
histologic fusion, with no ROM greater than 0.5[degrees] at the operative level in any loading mode. 
* No adverse tissue response was observed in any animal. A mild chronic inflammatory response to 
the degrading polylactide implants was observed at 6 and 12 months, whereas at 36 months there 
was no tissue reaction and the polylactide was completely resorbed. 
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Figure 1. Bioresorbable interbody implant fabricated from 70:30 poly(l-lactide-co-d,l-lactide) raw 
material. The implants measured 11 x 11 x 7 mm (width x length x height), with a 2-mm wall 
thickness. To allow radiographic monitoring of the radiolucent implant 0.5 mm O tantalum markers 
were inserted into each device (1 anteriorly and 2 posteriorly). 
 
 
 
 
Table 1. Mean Angular Range of Motion (Degrees) at Operative Level, and Adjacent Cranial and 
Caudal Levels 
Flexion Extension Lateral Bending Axial Rotation 
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 Crani
al 
Level 
Fusio
n 
Level 
Caud
al 
Level 
6 mo (n 
= 3 
animal
s) 
               
Max 13.18 0.35 15.71  14.69 0.30 16.56  18.71 0.40 15.70  8.16 0.26 15.87 
Min 5.48 0.18 8.53  6.39 0.13 10.06  14.07 0.11 14.27  3.10 0.18 7.56 
Avg 8.44 0.24 11.84  9.68 0.23 13.22  15.93 0.27 15.03  6.09 0.22 11.46 
12 mo 
(n = 3 
animal
s) 
               
Max 7.84 0.34 12.82  9.95 0.20 16.03  15.97 0.35 18.83  6.86 0.22 7.50 
Min 4.66 0.22 7.58  5.65 0.14 9.02  13.30 0.23 14.91  3.41 0.21 5.40 
Avg 6.02 0.30 10.09  7.41 0.16 12.22  14.36 0.27 17.46  4.79 0.21 6.41 
36 mo 
(n = 2 
animal
s) 
               
Max 8.64 0.40 14.92  10.46 0.38 21.40  14.48 0.24 21.38  6.34 0.29 14.80 
Min 6.84 0.09 13.45  9.32 0.09 15.13  14.47 0.06 15.94  4.70 0.10 3.76 
Avg 7.74 0.25 14.18  9.89 0.23 18.27  14.48 0.15 18.66  5.52 0.20 9.28 
 
 
 
Figure 2. Range of motion (ROM) results for each animal in flexion, extension, lateral bending, and 
axial rotation. Data are shown at the operative (fusion) level and at the adjacent cranial and caudal 
(unfused) levels. The maximum ROM observed in any loading mode at the operative level was less 
than 0.5[degrees]. (A) 6 month results; (B) 12 month results; (C) 36 month results. 
 
 
Figure 3. Histologic results at 6 months: (A) postsacrifice high-resolution lateral radiograph; (B) and (C) 
saggital undecalcified histologic section and corresponding microradiograph. Animal was graded as 
radiographically fused, and histologic evaluation demonstrated partial fusion. This histologic section 
shows no bony bridging. 
 
 
Figure 4. Histologic results at 12 months: (A) postsacrifice high-resolution lateral radiograph; (B) 
and (C) saggital undecalcified histologic section and corresponding microradiograph. Animal was 
graded as radiographically fused. Histologic sections confirmed solid fusion, with bone growth 
through the interior of the implant. One of the tantalum markers is visible in histologic section and 
microradiograph. 
 
 
 
Figure 5. Histologic results at 36 months: (A) postsacrifice high-resolution lateral radiograph; (B) 
and (C) saggital undecalcified histologic section and corresponding microradiograph. Animal was 
graded as radiographically fused. Histologic sections confirmed solid fusion, and complete 
resorption of the implant. One of the tantalum markers is visible in histologic section and 
microradiograph. 
